How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,138 results for

Child Safety Seat

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Tolerability of ISX (...) (Isoxsuprine HCL) in MS Relapses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03752307 Recruitment Status : Recruiting First Posted : November 23, 2018 Last Update Posted : December 3, 2018 See Sponsor: University of New

2018 Clinical Trials

62. A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03571594

2018 Clinical Trials

63. Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan

Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan (ACTION) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

64. A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers

in sexual relations with a woman of child-bearing potential, the subject or the subject's non-pregnant female partner must be using a highly effective contraceptive method Confirmed diagnosis of CF by seat chloride and/or genetics by referring clinician FEV1 >/= 50% of predicted Stable CF disease as judged by the Investigator Weight > 40 kg Exclusion Criteria (Cystic Fibrosis Participants) Clinically-significant (CS) abnormalities in medical history, screening laboratory results, physical or physical (...) A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2018 Clinical Trials

65. Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan (ACTION) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

66. Child passenger safety practices in the U.S.: disparities in light of updated recommendations. (PubMed)

Child passenger safety practices in the U.S.: disparities in light of updated recommendations. Children are best protected in motor vehicle collisions when properly using the appropriate restraint and sitting in a rear row. Racial and ethnic disparities have been reported in injury statistics and use of any restraint; however, predictors of safety seat use, being unrestrained, and sitting in the front seat have not been explored previously.To determine factors associated with child passenger (...) safety practices by race/ethnicity in a national sample of child passengers aged <13 years.Secondary analysis conducted in 2011 of the 2007, 2008, and 2009 National Survey of the Use of Booster Seats in which child passenger restraint use was observed directly. Age-stratified, survey-weighted chi-square and logistic regression analyses were conducted.Restraint use was observed for 21,476 children aged <13 years. A decline in child safety seat use and increase in being unrestrained were observed

2012 American journal of preventive medicine

67. Level of Knowledge and Habitual Concepts of Turkish Parents on Child Passenger Safety

objectives to Mother only Father study objectives to Father only Outcome Measures Go to Primary Outcome Measures : test score [ Time Frame: baseline ] test score that measures the level of knowledge on child passenger safety by a 10 item questionnaire Secondary Outcome Measures : Number of families using car seats properly [ Time Frame: baseline ] I will be evaluated in 4 categories: Connecting the baby to the car seat properly, Connecting the car seat to the car properly, Using the rear facing, Placing (...) Level of Knowledge and Habitual Concepts of Turkish Parents on Child Passenger Safety Level of Knowledge and Habitual Concepts of Turkish Parents on Child Passenger Safety - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2012 Clinical Trials

68. Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x (...) × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2017 Clinical Trials

69. Policy Statement--Child Passenger Safety. (PubMed)

Policy Statement--Child Passenger Safety. Child passenger safety has dramatically evolved over the past decade; however, motor vehicle crashes continue to be the leading cause of death of children 4 years and older. This policy statement provides 4 evidence-based recommendations for best practices in the choice of a child restraint system to optimize safety in passenger vehicles for children from birth through adolescence: (1) rear-facing car safety seats for most infants up to 2 years of age (...) ; (2) forward-facing car safety seats for most children through 4 years of age; (3) belt-positioning booster seats for most children through 8 years of age; and (4) lap-and-shoulder seat belts for all who have outgrown booster seats. In addition, a fifth evidence-based recommendation is for all children younger than 13 years to ride in the rear seats of vehicles. It is important to note that every transition is associated with some decrease in protection; therefore, parents should be encouraged

Full Text available with Trip Pro

2011 Pediatrics

70. Analysis of Child Passenger Safety Restraint Use at a Pediatric Emergency Department. (PubMed)

younger than or 13 years of age were surveyed over a 5-week period. Appropriate use of child passenger safety (CPS) restraints was determined using Alabama law and AAP recommendations. Use of Car Seat Checks provided by Children's Hospital and Safe Kids, knowledge of Alabama laws and CPS guidelines, and the source of information used by parents were ascertained.Among 525 patients identified, 520 (99.0%) participated. Appropriate use per Alabama law and AAP guidelines was 72.3% and 60.6%, respectively (...) Analysis of Child Passenger Safety Restraint Use at a Pediatric Emergency Department. The objectives of the study were to determine the number of children properly restrained during transit to a pediatric emergency department for care and to ascertain parental knowledge of Alabama laws and American Academy of Pediatrics (AAP) guidelines and where they obtain this information.An emergency department (patient care rooms) waiting area, convenience sample of Alabama parents who have children

2011 Pediatric Emergency Care

71. Protection of children restrained in child safety seats in side impact crashes. (PubMed)

Protection of children restrained in child safety seats in side impact crashes. The performance of child restraint systems (CRS) in side impact motor vehicle crashes has been under study due to the injury and fatality burden of these events. Although previous research has quantified injury risk or described injured body regions, safety advances require an understanding of injury causation. Therefore, the objective was to delineate injury causation scenarios for CRS-restrained children in side (...) impacts and document probable contact points in the vehicle interior.Two in-depth crash investigation databases, the Crash Injury Research and Engineering Network and the Partners for Child Passenger Safety Study, were queried for rear-seated, CRS-restrained children in side impact crashes who sustained Abbreviated Injury Scale 2+ injury. These cases were reviewed by a multidisciplinary team of physicians and engineers to describe injury patterns, injury causation, and vehicle components

2010 Journal of Trauma

72. Penetrating pediatric trauma owing to improper child safety seat use. (PubMed)

Penetrating pediatric trauma owing to improper child safety seat use. We present a case of a 15-month-old child with a history of thoracic impalement after improper safety seat restraint. The foreign body was stabilized with bulky dressings in the field before transport. Imaging revealed possible pulmonary artery involvement; and consequently, a thoracotomy was done to obtain vascular control before removal. We use this case to highlight prehospital care and operative management of a patient

2010 Journal of Pediatric Surgery

73. Promoting Safety: Alternative Approaches to the Use of Restraints

Promoting Safety: Alternative Approaches to the Use of Restraints BEST PRACTICE GUIDELINES • www.rnao.org 1 FEBRUARY 2012 Promoting Safety: Alternative Approaches to the Use of Restraints Clinical Best Practice Guidelines REGISTERED NURSES’ ASSOCIATION OF ONTARIO Promoting Safety: Alternative Approaches to the Use of Restraints Disclaimer These guidelines are not binding on nurses or the organizations that employ them. The use of these guidelines should be flexible, and based on individual (...) appear on all copied materials as follows: Registered Nurses’ Association of Ontario. (2012). Promoting Safety: Alternative Approaches to the Use of Restraints. T oronto, ON: Registered Nurses’ Association of Ontario. This Program is funded by the Ontario Ministry of Health and Long-T erm Care. Contact Information Registered Nurses’ Association of Ontario 158 Pearl Street, T oronto, Ontario M5H 1L3 Website: www.rnao.org/bestpractices BEST PRACTICE GUIDELINES • www.rnao.org 1 Greetings from Doris

2012 Registered Nurses' Association of Ontario

74. Carpooling and booster seats: a national survey of parents. (PubMed)

and carpooling.Of 1612 parents responding to the full survey (response rate = 71%), 706 had a 4- to 8-year-old child and 681 met inclusion rules. Most parents (76%) reported their child used a safety seat when riding in the family car. Of children reported to use seat belts, 74% did so in accordance with their state law. Parent report of child safety seat use was associated with younger child age and with the presence of state booster seat laws. Sixty-four percent of parents carpool. Among parents who carpool (...) and whose children use a child safety seat: 79% indicated they would always ask another driver to use a booster seat for their child and 55% reported they always have their child use their booster seat when driving friends who do not have boosters.Carpooling is a common driving situation during which booster seat use is inconsistent. Social norms and self-efficacy are associated with booster seat use. Clinicians who care for children should increase efforts to convey the importance of using the size

Full Text available with Trip Pro

2012 Pediatrics

75. Infant Car Seat

, Car seat for infants From Related Chapters II. Indications Newborns Infants under 20 to 22 pounds (under age 1 year) Infants head must be >1 inch below top of seat III. Positioning Seat always faces rear Semi-reclined position (45 degrees) maintains airway Rear-facing position supports head and neck Front-facing does not offer head and neck support Rear-facing position continued until Child over age 2 years and Child weight over 20 pounds Harness straps should be at or below level Carrier handle (...) , sun shield should be in down position IV. Benefits Doubles as a baby carrier Lightweight V. Recommended Infant Seat (Consumer Reports) Century 565 ($35) VI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Infant Car Seat." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Safety About FPnotebook.com is a rapid access, point

2015 FP Notebook

76. Built-In Car Seats

-In Car Seats , Integrated Child Seat From Related Chapters II. Indication Over 1 year old and over 20 pounds III. Description Available on some GM, Ford, Chrysler and Volvo Typically uses 5 point harness Converts to booster in many cases IV. Precautions Most versions lack head support for sleeping child Some new cars will include reclining design Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Built-In Car Seats." Click (...) Built-In Car Seats Built-In Car Seats Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Built-In Car Seats Built-In Car Seats Aka: Built

2015 FP Notebook

77. Booster Car Seat

Seat , Booster Seat From Related Chapters II. Indication Child age 4-8 years old or <57 inches tall See for guidelines III. Types High-back Booster Seat (includes harness system) Used for child over 20-30 pounds (over age 1 year) Child 40 pounds or less: Harness used Child over 40 pounds Harness removed from seat Seat raises child to use vehicle Clip at top of seat positions belt belt crosses mid-clavicle and mid-chest fits tightly over upper thighs High-back Booster Seat (without harness system (...) ) Used for child weight over 40 pounds Otherwise same as high-back Booster Seat above No-back or low-back shielded Booster Seat (avoid) Used for child over 40 pounds No head or neck protection in rear-end impact IV. Recommended Booster Seat Century Breverra Premiere 4885 or 4880 ($60) V. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Booster Car Seat." Click on the image (or right click) to open the source website

2015 FP Notebook

78. CPG on Attention Deficit Hyperactivity Disorder (ADHD) in the Child and Adolescent Population

CPG on Attention Deficit Hyperactivity Disorder (ADHD) in the Child and Adolescent Population Clinical Practice Guideline on Attention De? cit Hyperactivity Disorder (ADHD) in Children and Adolescents CLINICAL PRACTICE GUIDELINES IN THE SPANISH NATIONAL HEALTHCARE SYSTEM MINISTRY OF HEALTH, SOCIAL POLICY , AND EQUALITY MINISTERIO DE SANIDAD, POLÍTICA SOCIAL E IGUALDADIt has been 5 years since the publication of this Clinical Practice Guideline and it is subject to updating. Clinical Practice (...) it include? Recommendations 7.2.3.1. Personalised and speci? c treatment of teaching in academic competences and skills is recommended for children and adolescents with ADHD and repercussion on academic performance. 7.2.4. In ADHD in children and adolescents:What adaptations are useful/recommendable in the school context? Recommendations B 7.2.4.1. When ADHD has a signi? cant impact on the child’s or adolescent’s academic competence, the schools should make adaptations to help them in the classroom

2010 GuiaSalud

79. A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairmen

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairmen A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe (...) Ambulatory Impairment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE

2016 Clinical Trials

80. Study to Evaluate the Safety and Efficacy of Ace-ER Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

Study to Evaluate the Safety and Efficacy of Ace-ER Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>